Key Highlights

  • Net loss narrowed to USD 1.4 million from USD 9.9 million.
  • Loss per share was USD 0.26 versus USD 4.41 a year earlier.
  • Cash and cash equivalents were USD 18.7 million.
  • No Research and Development expense was incurred in the quarter.

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) reported a third-quarter 2026 net loss of USD 1,425,104 versus USD 9,906,504, or USD 0.26 per share versus USD 4.41, compared with an estimated loss of USD 1.58 per share in the Earnings data. The operating loss was USD 2,095,375 versus USD 5,652,689.

The company did not incur any research and development expense in the quarter after discontinuing development of BNC210 for social anxiety disorder and halting its internal preclinical programs. General and administrative expense rose 12.2% to USD 2,095,375 from USD 1,867,040, which the company attributed to higher professional services costs of USD 0.5 million, partly offset by lower headcount costs.

Other Income and Cash Flow

Other income was USD 635,478 versus an other loss of USD 4,288,608, a USD 4.9 million swing driven by differences in Fair Value adjustments on a Warrant Liability and a contingent consideration liability. Loss before income taxes was USD 1,459,897 versus USD 9,941,297.

Net cash used in Operating Activities was about USD 1.1 million versus USD 3.8 million. Financing provided less cash because the prior-year quarter included about USD 3.3 million from an at-the-market facility. Cash and cash equivalents were USD 18,744,060 versus USD 19,865,531 at the prior year-end, and total Assets were USD 27,105,149.

Interest income was USD 169,117 versus USD 141,996, and the foreign currency transaction loss was USD 192,515 versus USD 61,735. The warrant liability was USD 1,705,435 versus USD 1,971,172 at the prior year-end, and contingent consideration was USD 522,523 versus USD 1,025,301.

The gain on fair value adjustments was USD 790,884 versus a loss of USD 4,368,869, and the income tax benefit was USD 34,793 in both periods. Unrealized foreign currency translation gains were USD 220,549 versus USD 49,221, and 5,411,334 shares were outstanding.

Scancell Merger

On July 23, 2026, the company entered into a Merger agreement with Scancell Holdings plc. Each share of company common stock would convert into American Depositary Shares of the successor parent at an exchange ratio set in the agreement, plus one contingent value right.

The filing describes the company's principal activities as "completing the proposed merger", preserving cash, meeting public-company and contractual obligations and managing its interests in partnered programs. These include a license to Carina Biotech for BNC101 and a Merck agreement covering MK-1167, whose Phase 2 trial was terminated.

Goodwill and Items to Follow

Goodwill was carried at USD 3,527,809 at September 30, after a Goodwill Impairment charge of about USD 5.4 million recorded at June 30, 2026 tied to lower expected cash flows from potential MK-1167 commercialization. Management saw no further impairment indicators at September 30.

Items to follow include the merger conditions and timing, general and administrative cost levels, the cash balance and developments in the partnered programs.

Total current assets were USD 19,600,963 and total liabilities were USD 3,634,964 versus USD 4,108,994. Accounts Payable rose to USD 724,696 from USD 385,584, shareholders' Equity was USD 23,470,185 and the accumulated Deficit was USD 193,223,738.